← All trials
NCT04469556
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2020
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2023
- First posted
- Jul 14, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Harvard UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- Johns Hopkins UniversityStudy chair
- University of TorontoStudy chair
- Ontario Institute for Cancer ResearchCollaborator
- Stand Up To CancerCollaborator
- Cold Spring Harbor LaboratoryCollaborator
- Memorial Sloan-Kettering Cancer CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.